Active Clinical Trials for Mesothelioma Cancer

This page lists many active clinical trials (protocols) at Fox Chase Cancer Center for Mesothelioma cancer. In addition to the title, some studies below have brief summaries.

Clinical trials, or protocols, are research studies conducted with people who volunteer to take part. You benefit by having access to new cancer treatments and options not otherwise available, in addition to the excellent care offered at Fox Chase.

For more information on clinical trials at Fox Chase Cancer Center, or to find a study, call 1-888 FOX CHASE (1-888-369-2427).
Open DateTrial NumberPrincipal InvestigatorTitle
02/24/2012RRC2012/12-811Hossein Borghaei Aurora A Expression In Lung Cancer Tumors
07/13/2015S1400/14-706Hossein Borghaei Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
01/02/201815-1009/15-1009Anthony Olszanski A Phase I Dose-Escalation Study of ONC201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
10/28/201515-7002/15-7002Lori Goldstein Molecular Analysis for Therapy Choice (MATCH)
02/15/201715-9041/15-9041Deric Savior Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies - A Trial of the AIDS Malignancy Consortium
05/06/201615-1081/15-1081Wafik El-Deiry A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
07/25/201616-1028/16-1028Hossein Borghaei Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB00100718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies
07/07/201716-1071/16-1071Anthony Olszanski A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination with Anticancer Agents in Subjects with Selected Advanced Solid Tumors
02/15/201716-1080/16-1080Jessica Bauman Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy
07/17/201716-9050/16-9050Hossein Borghaei Isolation and Characterization of Novel Antibodies Generated by Patients Treated With Anti PD-1/PD-L1 Antibodies
05/30/201716-1101/16-1101Anthony Olszanski A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies
06/27/201717-1003/17-1003Hossein Borghaei Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
04/24/201717-1006/17-1006Martin Edelman A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma
07/07/201717-1014/17-1014Anthony Olszanski A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
01/02/201817-1022/17-1022Anthony Olszanski A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers
02/22/201817-1025/17-1025Yanis Boumber A Multi-arm, Phase Ib, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have Progressed Following Therapy with an EGFR TKI (TATTON)
06/02/201717-9020/17-9020Jessica Bauman Frequency of End of Life Discussions in Oncology Fellow Clinics at Fox Chase Cancer Center
12/11/201717-1035/17-1035Anthony Olszanski A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies
04/12/201817-1033/17-1033Anthony Olszanski Phase 1 Dose Escalation, Multi-Tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4c1032T in HLA-A2+ Subjects with MAGE-A4 Positive Tumors.
11/21/201717-1042/17-1042Anthony Olszanski A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination with Palliative Radiotherapy in Subjects with Solid Tumors
04/06/201817-1045/17-1045Martin Edelman A Phase I Dose Escalation, Open-Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
01/15/201817-1050/17-1050Martin Edelman Depletion of Myeloid Derived Suppressor Cells to Enhance anti PD-1 Therapy
12/13/201717-1051/17-1051Anthony Olszanski A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
12/04/201717-1052/17-1052Hossein Borghaei A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
12/15/201717-2009/17-2009Deric Savior Protocol A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
01/18/201817-8011/17-8011Hossein Borghaei Prospective Validation Trial for Non-Small Cell Lung Cancer Salivary Biomarkers
06/06/201817-1079/17-1079Crystal Denlinger A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors
12/15/201717-2017/17-2017Deric Savior Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
12/15/201717-2016/17-2016Deric Savior A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
12/15/201717-2015/17-2015Deric Savior Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) ? A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
07/19/201818-1003/18-1003Hossein Borghaei An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1/PD-L1 Containing Therapy
10/19/201818-1008/18-1008Angela Jain A Phase 1b/2 Study to Evaluate Safety and Anti-Tumor Activity of Avelumab in Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Locally Advanced or Metastatic Solid Tumors
08/08/201818-1016/18-1016Margaret von Mehren First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (HuMax-AXL-ADC) in Patients With Solid Tumors
07/19/201818-2010/18-2010Jessica Bauman Phase II Study of AZD9291 (osimertinib) in advanced NSCLC patients with exon 20 insertion mutations in EGFR
10/17/201818-1035/18-1035Martin Edelman A Phase 1/2, Open Label, Multicenter Study of the Combination of NKTR-214 and nivolumab or the Combination of NKTR-214, nivolumab and ipilimumab in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
09/24/201818-1038/18-1038Anthony Olszanski An Open Label, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TAK-981 in Adult Patients With Metastatic Solid Tumors or Lymphomas
08/04/201414-036/14-036Marc Smaldone SURG-073: A Randomized Controlled Trial of Perioperative Risk Stratification and Risk-Based, Protocol-Driven Management in Patients Undergoing Elective Major Cancer Surgery ("Perioperative Risk Study")
03/24/1997IRB96011/96-011Margie Clapper Genetic Susceptibility In Lung Cancer
01/28/2015IRB14829/14-829Margie Clapper Assessment of Secondhand Smoke Exposure and the Gene Expression Profile of the Nasal Epithelium as Biomarkers of Lung Cancer Risk
08/27/201817-8013/17-8013Sarah Bass Mychoice: Testing an Interactive mHealth Tool to Enhance Communication and Informed Decision Making About Clinical Trial Participation in Cancer Patients
05/15/201817-1057/17-1057Christopher Manley TH-112: Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate
03/08/2000IRB89061/89-061Jospeh Testa Molecular Genetic Alterations in Human Lung Cancer and Mesothelioma
12/05/201717-8012/17-8012Jeffrey Farma Prospective Collection of Characteristics and Outcome of Patients Treated for Sarcoma at Fox Chase Cancer Center
08/27/201817-2013/17-2013Stacey Su Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
12/12/2014TEMPLECALGB30610/14-911Mark Hallman Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide
02/24/201716-1051/16-1051Joshua Meyer Phase I Study of Neoadjuvant Pulsed Low Dose Rate Radiation with Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer
02/24/201716-8010/16-8010Joshua Meyer Observation Study of Patients with Non-Small Cell Lung Cancer and Esophageal Cancer Treated with Chemo-Radiation Followed by Surgery
10/17/201818-9021/18-9021Stephanie Weiss Retrospective Analysis of Patients Treated with Radiosurgery for Brain Metastases from ALK Rearranged and EGFR Mutated NSCLC
01/20/201716-8011/16-8011Kuang-Yi Wen Preventing Postpartum Smoking Relapse: A Twitter-Enabled Supportive Intervention (Smkfree4baby)